Washington, D.C. — In a Presidential Determination submitted to Congress, U.S. President Donald Trump named 23 countries, including India, China, Pakistan, and Afghanistan, as major drug transit or illicit drug-producing nations. The designations urge stronger action, particularly regarding synthetic drugs and precursor chemicals, amid a mounting public health and national security crisis in the U.S
Key Highlights of the Determination
- The U.S. State Department clarified that being on the list does not necessarily mean a country has failed in its counter-narcotics efforts. Rather, inclusion is based on geographic, economic, and commercial factors that allow drug production or trafficking.
- Five countries — Afghanistan, Bolivia, Burma (Myanmar), Colombia, and Venezuela — were singled out as having “failed demonstrably” in the past year to meet international obligations
- China is specifically called out as the largest global source of precursor chemicals used for fentanyl production, and other synthetic narcotics (such as nitazenes and methamphetamine) are also part of the concern.
- In Afghanistan, despite public bans, the U.S. claims the drug trade continues — including opiates and rising methamphetamine production — and that revenue from drugs is funding both transnational crime and terrorism.
Reactions
India
Indian authorities have expressed strong disagreement with the listing. They argue that being classified as a “major transit or producing country” overshadows India’s significant efforts to tighten regulation of precursor chemicals, expand enforcement activities, and cooperate with international partners. Delhi has emphasized that the designation is based on trafficking geography rather than a failure of intent, pointing out that legal frameworks and enforcement efforts are active.
China
Beijing has issued a statement rejecting the characterization that it is the world’s primary source of precursor chemicals for illicit drugs. China’s government insists it has enacted several regulatory measures to monitor and restrict the export of such chemicals. Chinese officials say they find the U.S. assertion to be misrepresentative and have called for concrete evidence. They also point out that international cooperation remains the better path forward rather than unilateral labeling.
Pakistan
Pakistan’s reaction has been one of concern, arguing that it is unfairly singled out without sufficient consideration for its domestic efforts against drug trafficking. Islamabad maintains it has enacted stronger border controls, stepped up law enforcement operations, and collaborated with U.S. and regional agencies. Pakistani officials urge that cooperation, not accusations, should guide international narcotics policy.
Afghanistan
The inclusion has provoked sharp responses from the Taliban-led government, which claims that recent bans and enforcement steps have significantly reduced production of certain narcotics. They argue U.S. criticism overlooks both the logistical challenges they face and ongoing conflict-related disruptions. Nonetheless, U.S. statements allege that the drug trade persists, including in methamphetamine, and that profits benefit elements inside the Taliban.
U.S. Response & Next Steps
The Trump administration insists the listing is meant to press for stronger cooperation, better law enforcement, and stricter regulation of chemicals linked to synthetic drug manufacturing. Washington is pushing for:
- Increased information sharing among governments
- Prosecutions of individuals and entities trafficking precursor chemicals
- Enhanced border and transit route security
- A more coordinated international approach under counter-narcotics treaties
The State Department has emphasized that countries can improve their standing with U.S. policy by taking “substantial efforts” in the coming year.